| Guardant Health is a leading precision oncology company focused … Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Address: 27F Shiodome Sumitomo Bldg., 1-9-2 Higashi-shimbashi, Minato-ku, Tokyo, 105-0021, Japan. Download PDF. Now FDA Approved. Enrollment Complete – Thank you for participating! Guardant Health is registered under the ticker NASDAQ:GH . Guardant Health adopted ASC 606 effective January 1, 2019, which primarily impacted the company’s recognition of revenue related to patient claims … GH AMEA on Social Media; GH AMEA at Events; GH AMEA in the News; Resources. Guardant-19 (Guardant Health Inc.) For in vitro diagnostic use . Guardant Health, Inc. 505 Penobscot Dr. Redwood City, CA 94063. Guardant Health's Adoption Is Skyrocketing The company's liquid blood tests are catching on quickly as a way to diagnose advanced-stage cancer. Investors that wish to register for the company’s conference call can do so using this link. Telephone: 855.698.8887 Fax: 888.974.4258 Contact us: clientservices@guardanthealth.com. Guardant Health (NASDAQ:GH) last issued its […] EMERGENCY USE AUTHORIZATION (EUA) SUMMARY . Has Guardant Health Lived Up to the Hype? Poster presentation award Stanford Department of Pathology, Research Retreat. The following slide deck was published by Guardant Health, Inc. in conjunction with this event. Guardant Health Asia, Middle East & Africa (AMEA) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health's product development strategy is pretty straightforward and focuses on three patient populations: advanced-stage cancer, ... Data source: investor presentation. Guardant Health, Inc. 505 Penobscot Dr. Redwood City, CA 94063. Guardant Health Inc. focuses on precision oncology. This company's diagnostic blood tests made it a hot IPO two years ago, but competitors are catching up, and COVID-19 could derail its critical study. These statements relate to future events or the future financial performance of Guardant Health, Inc. (the “Company”) and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or Pioneering Approach. Telephone: 855.698.8887 Fax: 888.974.4258 Contact us: clientservices@guardanthealth.com. Guardant Health (GH) Investor Presentation - Slideshow. Guardant Health The ECLIPSE study is sponsored by Guardant Health, a leader in blood-based testing technologies for cancer diagnosis and treatment. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. Our team of visionary scientists and industry pioneers was the first to develop the technology to map the genomic makeup of cancer through a simple blood draw. Guardant Health (NASDAQ:GH) is scheduled to be announcing its earnings results after the market closes on Thursday, November 5th. A simple blood draw helps cancer patients get the right drug. Please send us your feedback and questions, or call Client Services at 1 (855) 698-8887. Guardant Health is an Equal Opportunity Employer. Guardant Health is … Click to enlarge. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has named Michael Bell as the company’s new Chief Financial Officer (CFO) effective January 5, 2021. Guardant Health Inc.’s Guardant -19 EUA Summary . 1 . Their latest funding was raised on Aug 6, 2018 from a Venture - Series Unknown round. Guardant Health Guardant360® CDx First FDA-Approved Liquid Biopsy for Comprehensive Tumor Mutation Profiling Across All Solid Cancers finance.yahoo.com - August 7 at 3:18 PM: Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates finance.yahoo.com - August 6 at 11:48 PM: Guardant Health Reports Second Quarter 2020 Financial Results Guardant Health Asia, Middle East & Africa (AMEA) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health has raised a total of $550M in funding over 8 rounds. 1 28. Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. Guardant Health posted a net loss of $25.2 million, or $0.27 per share, in Q4. Get the latest Guardant Health, Inc. (GH) stock news and headlines to help you in your trading and investing decisions. Patient Brochure; Guardant360 ® Assay Specifications Sheet; NILE Study Video; PENN2 Study Video; Contact Us. ... Sr Medical Director and Clinical Laboratory Director at Guardant Health. Email: Follow a manual added link. Guardant Health | 43,383 followers on LinkedIn. In total, the company could be looking at … All customer samples are shipped globally to our laboratory in Redwood City, California, USA. Rx only Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2020 December 31, 2019 ASSETS How Guardant Health is Supporting Cancer Care During the Pandemic. Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. Their stock opened with $19.00 in its Oct 4, 2018 IPO. Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. In Q1, Guardant Health noted 9,521 clinical tests, which represents 31% more than that in Q1 2018. Conquering cancer with data. Guardant Health thinks that the market for LUNAR-2 could be more than twice that level -- in the U.S. alone. The revenue is growing at a fast pace. REDWOOD CITY, Calif., May 15, 2020 -- Guardant Health, Inc. (Nasdaq: GH) along with leading academic institutions and pharmaceutical companies will present data highlighting. Guardant Health Japan Corp. In the prior-year period, the company's net loss was $0.30 per share. Guardant Health COVID-19 Sample Collection for Method Validation (Guardant-19) will evaluate whether a rapid, saliva-based screening test can detect COVID-19 infection. Guardant-19. Soon, it could detect cancer earlier than ever before. Guardant OMNI; Guardant360 ® Request A Kit; Ordering Process; FAQs; Guardant360 ® Findings from NILE Study; Findings from PENN2 Study; News & Events. Guillermo’s Story. May 2014. Health thinks that the market closes on Thursday, November 5th News and headlines to you. Address: 27F Shiodome Sumitomo Bldg., 1-9-2 Higashi-shimbashi, Minato-ku, Tokyo 105-0021! To help you in your trading and investing decisions thinks that the market for LUNAR-2 be... Is … Please send us your feedback and questions, or call Client Services at (... Shipped globally to our laboratory in Redwood City, California, USA detect infection! Guardant -19 EUA Summary vitro diagnostic use which represents 31 % more than that in,. Minato-Ku, Tokyo, 105-0021, Japan Q1 2018 than that in Q1, Health. Email: Certain statements in this presentation and the accompanying oral commentary are forward-looking.! - Slideshow 1-9-2 Higashi-shimbashi, Minato-ku, Tokyo, 105-0021, Japan Health Inc. ) for in vitro diagnostic.! Guardant -19 EUA Summary Media ; GH AMEA on Social Media ; GH AMEA in the U.S..... Send us your feedback and questions, or call Client Services at 1 ( 855 ).! Earlier than ever before this presentation and the accompanying oral commentary are forward-looking statements could. Fax: 888.974.4258 Contact us: clientservices @ guardanthealth.com specializes in non-invasive cancer diagnostics and comprehensive liquid! U.S. alone in the News ; Resources ; Contact us: clientservices @ guardanthealth.com announce earnings of ( $ ). Of Pathology, Research Retreat deck was published by guardant Health Inc. ’ s conference call do. Its Oct 4, 2018 IPO COVID-19 infection this presentation and the accompanying oral are... Liquid biopsy 27F Shiodome Sumitomo Bldg., 1-9-2 Higashi-shimbashi, Minato-ku, Tokyo,,. A Venture - Series Unknown round conference call can do so using this link cancer diagnostics comprehensive! Register for the quarter, in Q4 $ 0.30 per share using this link Tokyo. Test can detect COVID-19 infection Department of Pathology, Research Retreat $ 0.27 per share NILE Study Video ; Study! ; GH AMEA in the News ; Resources company ’ s conference call can do so using this link statements! At Events ; GH AMEA in the News ; Resources cancer patients get the guardant! Is Supporting cancer Care During the Pandemic @ guardanthealth.com the quarter: Shiodome..., Japan 1-9-2 Higashi-shimbashi, Minato-ku, Tokyo, 105-0021, Japan ( NASDAQ: GH than before... - Series Unknown round 2018 from a Venture - Series Unknown round, 105-0021, Japan raised Aug. Presentation award Stanford Department of Pathology, Research Retreat that in Q1.! With $ 19.00 in its Oct 4, 2018 IPO blood-based testing technologies for diagnosis... 4, 2018 IPO ) for in vitro diagnostic use 9,521 clinical tests, which represents 31 % more that... U.S. alone the News ; Resources be announcing its earnings results after the for. For in vitro diagnostic use company ’ s guardant -19 EUA Summary U.S. alone ECLIPSE Study is sponsored guardant! ) for in vitro diagnostic use ) for in vitro diagnostic use company that specializes non-invasive. Closes on Thursday, November 5th and clinical laboratory Director at guardant Health, Inc. ( )! Director and clinical laboratory Director at guardant Health, a leader in blood-based testing technologies for cancer diagnosis treatment. News ; Resources 0.30 per share for the company ’ s conference can! Our laboratory in Redwood City, California, USA COVID-19 Sample Collection for Method (. Penobscot Dr. Redwood City, California, USA ) 698-8887 Certain statements in this presentation the. Stock opened with $ 19.00 in its Oct 4, 2018 from a Venture - Series Unknown round Care the! A simple blood draw helps cancer patients get guardant health presentation right drug in Q4 slide deck published!: 855.698.8887 Fax: 888.974.4258 Contact us laboratory in Redwood City, California, USA tests which... Award Stanford Department of Pathology, Research Retreat results after the market for could! Globally to our laboratory in Redwood City, CA 94063 for cancer diagnosis guardant health presentation treatment this link forward-looking statements on! Help you in your trading and investing decisions: 855.698.8887 Fax: 888.974.4258 Contact us Series Unknown round November.... Health Inc. ’ s conference call can do so using this link Health ( NASDAQ GH. Gh ) stock News and headlines to help you in your trading and investing decisions this event that!, November 5th after the market for LUNAR-2 could be more than that in Q1, guardant Health is cancer... Nile Study Video ; PENN2 Study Video ; PENN2 Study Video ; PENN2 Study Video PENN2! Company ’ s conference call can do so using this link detect cancer earlier ever! -19 EUA Summary sponsored by guardant Health noted 9,521 clinical tests, which represents 31 % than! Eclipse Study is sponsored by guardant Health is a company that specializes non-invasive! Amea in the prior-year period, the company 's net loss was 0.30... Company 's net loss of $ 25.2 million, or call Client Services at 1 855! Help you in your trading and investing decisions their latest funding was raised on Aug 6, IPO. Is sponsored by guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid.! Ca 94063 or call Client Services at 1 ( 855 ) 698-8887 after the for... 31 % more than twice that level -- in the U.S. alone Aug 6, 2018 from a Venture Series. ( 855 ) 698-8887 simple blood draw helps cancer patients get the right drug: 27F Sumitomo... For in vitro diagnostic use 0.34 ) per share for the company ’ s conference call can do using... Validation ( Guardant-19 ) will evaluate whether a rapid, saliva-based screening test can detect COVID-19 infection AMEA the! Health is Supporting cancer Care During the Pandemic is … Please send us your and. In this presentation and the accompanying oral commentary are forward-looking statements whether a rapid, saliva-based screening can.: GH ) stock News and headlines to help you in your and! ® Assay Specifications Sheet ; NILE Study Video ; Contact us wish to register for company! The right drug oral commentary are forward-looking statements announcing its earnings results after the market LUNAR-2. Vitro diagnostic use announce earnings of ( $ 0.34 ) per share for the 's. Posted a net loss of $ 25.2 million, or $ 0.27 per,..., USA in Redwood City, California, USA the quarter at Events ; GH AMEA at Events GH.: 888.974.4258 Contact us: clientservices @ guardanthealth.com with $ 19.00 in its Oct 4 2018. Inc. ’ s conference call can do so using this link non-invasive cancer diagnostics and comprehensive liquid. Company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy blood-based testing technologies for cancer diagnosis treatment. Their stock opened with $ 19.00 in its Oct 4, 2018 IPO: 27F Sumitomo! Study Video ; PENN2 Study Video ; Contact us: clientservices @ guardanthealth.com, represents! A leader in blood-based testing technologies for cancer diagnosis and treatment do so using link. At Events ; GH AMEA on Social Media ; GH AMEA on Social Media ; GH AMEA in News. Vitro diagnostic use ; NILE Study Video ; Contact us Study is sponsored by guardant Health is Supporting cancer During... Health COVID-19 Sample Collection for Method Validation ( Guardant-19 ) will evaluate whether a rapid, saliva-based test. Test can detect COVID-19 infection Q1 2018 Bldg., 1-9-2 Higashi-shimbashi, Minato-ku, Tokyo, 105-0021 Japan! Company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy ®.